Kidney disease is one of the most serious and common complications associated with aging and diabetes. As people grow older, kidney function naturally declines, increasing the risk of chronic kidney disease, cardiovascular problems, and reduced quality of life. In recent years, a class of medications known as SGLT2 inhibitors has attracted growing attention for its ability to protect the heart and kidneys, even in people without diabetes.
Now, a new study published in the journal Kidney International offers fresh insight into how these drugs may actually slow the biological aging of the kidneys. Using a fast-aging species of fish, researchers were able to observe decades worth of kidney aging in a matter of weeks, revealing protective effects that go far beyond glucose control.
This research adds to a growing body of evidence suggesting that SGLT2 inhibitors may play an important role in preserving kidney health as people age.
SGLT2 inhibitors, or sodium-glucose cotransporter-2 inhibitors, are a class of prescription medications commonly used to treat type 2 diabetes. Popular examples include empagliflozin, dapagliflozin, and canagliflozin. These drugs work by preventing the kidneys from reabsorbing glucose back into the bloodstream. Instead, excess glucose is excreted through urine, helping lower blood sugar levels.
Over the past decade, large clinical trials have shown that SGLT2 inhibitors do more than manage blood sugar. They significantly reduce the risk of heart failure, slow the progression of chronic kidney disease, and lower the likelihood of hospitalization for cardiovascular events. These benefits have been observed even in patients without diabetes, raising important questions about how these drugs work at a deeper biological level.
To better understand the kidney-protective effects of SGLT2 inhibitors, researchers turned to an unusual but powerful model organism: the African turquoise killifish.
This small freshwater fish has an exceptionally short lifespan of just four to six months. Because it ages so rapidly, scientists can study age-related changes in organs like the kidney in a fraction of the time it would take using mice or other laboratory animals.
According to the research team, the kidney structure and aging patterns of the killifish closely resemble those seen in humans. As the fish age, their kidneys undergo changes that mirror human kidney aging and disease, including loss of small blood vessels, damage to filtration units, inflammation, and impaired energy production within kidney cells.
This made the killifish an ideal model for studying how aging affects kidney function and whether medications could slow that process.
The study, led by researchers at the MDI Biological Laboratory and Hannover Medical School, tested SGLT2 inhibitors on aging killifish and compared them with untreated fish. The results were striking.
As untreated fish aged, their kidneys showed progressive structural damage. This included deterioration of the glomeruli, which are tiny filtering units responsible for removing waste from the blood. There was also significant loss of capillaries, the small blood vessels that deliver oxygen and nutrients to kidney tissue.
Fish treated with SGLT2 inhibitors maintained healthier kidney architecture. Their filtering systems remained more intact, and blood flow within the kidneys was better preserved.
One of the most important discoveries involved capillaries. Aging kidneys tend to lose these vital blood vessels, which leads to reduced oxygen supply. When kidney cells do not receive enough oxygen, they shift to less efficient energy pathways, increasing inflammation and accelerating tissue damage.
The treated fish retained more capillaries as they aged. Gene activity in their kidneys resembled that of younger animals, suggesting that the drugs helped slow or reverse age-related vascular decline.
Kidney cells require a large amount of energy to perform their filtering functions. In aging and diseased kidneys, mitochondrial function often declines, impairing energy production.
The study found that SGLT2 inhibitors helped maintain more normal energy metabolism in kidney cells. This improved efficiency reduced cellular stress and inflammation, two major drivers of chronic kidney disease progression.
Chronic inflammation is a hallmark of kidney aging and disease. Researchers observed increased inflammatory signals in untreated aging fish, similar to patterns seen in human kidney disease.
In contrast, fish receiving SGLT2 inhibitors showed significantly lower levels of inflammation. Their kidney cells also communicated more effectively with one another, supporting healthier overall organ function.
SGLT2 inhibitors are already widely prescribed for people with diabetes and chronic kidney disease. However, this study helps explain why the benefits of these drugs often exceed what would be expected from blood sugar control alone.
According to Dr. Hermann Haller, senior author of the study and president of MDI Biological Laboratory, the results provide a biological explanation for clinical observations seen in patients.
The drugs appear to act on multiple interconnected systems within the kidney, including blood vessels, energy metabolism, and immune signaling. This multi-layered effect may explain why patients taking SGLT2 inhibitors experience slower kidney decline and better cardiovascular outcomes.
While fish are not humans, the aging processes observed in the killifish closely resemble those seen in people. This makes the findings especially relevant for understanding how these medications might influence kidney aging in real-world patients.
Chronic kidney disease affects millions of people worldwide and is strongly linked to aging. Even individuals without diabetes experience gradual kidney function loss over time, increasing vulnerability to illness and medication side effects.
If SGLT2 inhibitors can slow kidney aging at a biological level, their potential use could expand far beyond diabetes treatment. Researchers are particularly interested in whether these drugs could be used earlier in life or in non-diabetic populations to preserve kidney health.
The study also highlights the importance of protecting kidney blood vessels. Maintaining healthy capillaries appears to be a key factor in preventing energy failure and inflammation within kidney tissue.
The research team plans to use the fast-aging killifish model to answer additional questions that would take years to study in humans or traditional lab animals.
Future studies will explore whether SGLT2 inhibitors can repair kidney damage after it has already begun. Researchers also want to understand whether the timing of treatment matters, such as whether starting therapy earlier in life provides greater protection than beginning after kidney disease has developed.
Because the killifish model allows for rapid testing, it could also accelerate the development of new drugs aimed at slowing organ aging.
For patients currently taking SGLT2 inhibitors, this research offers reassurance that the benefits of these medications may extend beyond glucose control and symptom management. The drugs may be helping preserve kidney structure and function at a fundamental biological level.
However, experts caution that these findings should not be interpreted as a reason to start or change medication without medical guidance. While animal studies provide valuable insights, clinical decisions must always be based on individual health factors and physician recommendations.
The discovery that diabetes drugs may slow kidney aging represents an important step forward in understanding how modern medications can influence the biology of aging itself. By preserving blood vessels, reducing inflammation, and supporting cellular energy production, SGLT2 inhibitors may help protect one of the body’s most vital organs as it ages.
As research continues, these findings could open the door to new strategies for preventing kidney disease and promoting healthier aging across a wider population.
MDI Biological Laboratory. News release, January 30, 2026.
Study published in Kidney International.
This article is for informational and educational purposes only. It does not provide medical advice, diagnosis, or treatment. Statistical data and research findings describe general trends and may not apply to individual cases. Health conditions and responses to medication vary widely. Always consult a qualified healthcare professional before making decisions about medications or medical care.
Most Accurate Healthcare AI designed for everything from admin workflows to clinical decision support.